首页> 外文OA文献 >Plasmodium falciparum: new molecular targets with potential for antimalarial drug development
【2h】

Plasmodium falciparum: new molecular targets with potential for antimalarial drug development

机译:恶性疟原虫:具有抗疟药物开发潜力的新分子靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malaria remains one of the world's most devastating infectious diseases. Drug resistance to all classes of antimalarial agents has now been observed, highlighting the need for new agents that act against novel parasite targets. The complete sequencing of the Plasmodium falciparum genome has allowed the identification of new molecular targets within the parasite that may be amenable to chemotherapeutic intervention. In this review, we investigate four possible targets for the future development of new classes of antimalarial agents. These targets include histone deacetylase, the aspartic proteases or plasmepsins, aminopeptidases and the purine salvage enzyme hypoxanthine-xanthine-guanine phosphoribosyltransferase.
机译:疟疾仍然是世界上最具破坏力的传染病之一。现在已经观察到对所有类型的抗疟药都具有耐药性,这凸显了对新药的需求,这些新药可对抗新型寄生虫靶标。恶性疟原虫基因组的完整测序已允许在寄生虫内鉴定出新的分子靶标,这些靶标可能适合进行化学治疗。在这篇综述中,我们研究了新型抗疟药未来发展的四个可能目标。这些靶标包括组蛋白脱乙酰基酶,天冬氨酸蛋白酶或纤溶酶,氨肽酶和嘌呤挽救酶次黄嘌呤-黄嘌呤-鸟嘌呤磷酸核糖基转移酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号